Nasdaq
$22.00▲ 4.17%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $227.8MShares out 10.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 10.2After-hours26.10.03 05:134Ownership#●●●
BIODESIX INC
Insider John Patience of Biodesix Inc. reported changes in beneficial ownership of securities as of September 30, 2026. This filing is a standard Form 4 disclosure regarding insider stock transactions.…more
$22.00+4.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.12After-hours26.08.13 06:554Ownership
BIODESIX INC
Jack W. Schuler, a director at Biodesix Inc. (BDSX), filed a Form 4 report regarding insider transactions of company shares on August 10, 2026. This filing serves as an official update to the director's beneficial ownership status.…more
$22.00+4.17%vs prev closeView filingShare - 8.5After-hours26.08.06 05:0510-QEarnings
BIODESIX INC
바이오데식스(Biodesix)는 2026년 4월 1일부로 프리놈(Freenome)과 폐 결절 위험 계층화를 위한 혈액 기반 자가항체 검사 제품 공급 계약을 체결했습니다. 이번 계약은 기존의 임시 합의를 대체하며, 향후 협력 제품의 제조 및 공급에 관한 독점적 라이선스 및 공급 권한을 확정했습니다.…more
$22.00+4.17%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 19:00#●●●#●●●
Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026…more
Biodesix announced it will release its financial results for the third quarter of 2026 after the market closes on November 5. Management will host a conference call to discuss the results and provide a business update.…more
$22.00+4.17%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 5d agoAfter-hours26.10.20 05:01
●●●●●●●● ●●●●● ●●●●●●
The American College of Chest Physicians (CHEST) has published a new clinical framework that recommends Biodesix's biomarker testing as a core component for lung nodule risk stratification. This inclusion validates the clinical value of the company's diagnostic tools in standardizing patient care pathways.…more
$22.00+4.17%vs prev close - 6d agoPre-market26.10.19 19:00
●●●●●●●● ●●●●● ●●●●●●
Biodesix is partnering with Vanderbilt University to develop a multimodal diagnostic platform combining blood and imaging biomarkers with AI. While the company targets a 2028 commercial launch, the announcement represents an early-stage strategic initiative rather than immediate financial impact.…more
$22.00+4.17%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report